Author
Listed:
- Gia Deyab
- Trine Marita Reine
- Tram Thu Vuong
- Trond Jenssen
- Gunnbjørg Hjeltnes
- Stefan Agewall
- Knut Mikkelsen
- Øystein Førre
- Morten Wang Fagerland
- Svein Olav Kolset
- Ivana Hollan
Abstract
The endothelial glycocalyx (EG) is essential for proper function of the endothelium and for vascular integrity, but its role in premature atherogenesis in rheumatoid arthritis (RA) has not been studied yet. EG impairment can play a role in pathogenesis of vascular disease, and one of its characteristics is shedding of syndecan-1 from endothelial cells. Syndecan-1 shedding is mediated by matrix metalloproteinase-9 (MMP-9) and counteracted by tissue inhibitor of metalloproteinases (TIMP)-1. Cardiovascular disease risk in RA is reversible by disease modifying antirheumatic drugs (DMARDs), but the exact modes of action are still unclear. Therefore, we examined effects of DMARDs on syndecan-1, MMP-9 and TIMP-1 in RA patients, and searched for associations between these parameters and inflammatory activity. From the observational PSARA study, we examined 39 patients starting with methotrexate (MTX) monotherapy (in MTX naïve patients, n = 19) or tumor necrosis factor inhibitors (TNFi) in combination with MTX (in MTX non-responders, n = 20) due to active RA. Serum syndecan-1, MMP-9 and TIMP-1 were measured at baseline and after six weeks of treatment. Serum syndecan-1 (p = 0.008) and TIMP-1 (p
Suggested Citation
Gia Deyab & Trine Marita Reine & Tram Thu Vuong & Trond Jenssen & Gunnbjørg Hjeltnes & Stefan Agewall & Knut Mikkelsen & Øystein Førre & Morten Wang Fagerland & Svein Olav Kolset & Ivana Hollan, 2021.
"Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis,"
PLOS ONE, Public Library of Science, vol. 16(7), pages 1-11, July.
Handle:
RePEc:plo:pone00:0253247
DOI: 10.1371/journal.pone.0253247
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0253247. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.